CALIFORNIA LEGISLATURE 20172018 REGULAR SESSION Assembly Bill No. 395Introduced by Assembly Member BocanegraFebruary 09, 2017 An act to amend Sections 11839.1, 11839.2, and 11839.6 of the Health and Safety Code, relating to public health. LEGISLATIVE COUNSEL'S DIGESTAB 395, as introduced, Bocanegra. Alcohol and drug treatment programs.Existing law generally requires the State Department of Health Care Services to be responsible for licensing narcotic treatment programs to use narcotic replacement therapy in the treatment of addicted persons and makes legislative findings in support of coordinated narcotic treatment programs in this regard. Existing law specifies the controlled substances a licensed narcotic treatment program may use for narcotic replacement therapy. Existing law authorizes the department to approve an office-based narcotic treatment program in a remote site, if certain conditions are met, that include among others, a physician at a remote site may treat up to a maximum number of 20 patients, who are provided with a specific pharmacological treatment.This bill would make legislative findings and declarations that it is in the best interest of the health and welfare of the people of this state to also coordinate medication-assisted treatments for substance abuse disorders. The bill would modify the specific controlled substances authorized for use in narcotic replacement therapy to include medication-assisted treatment and refer to medications, rather than controlled substances. The bill would modify the conditions for the department to authorize an office-based narcotic treatment program in a remote site to authorize a physician to treat a number of patients specified under the United States Drug Enforcement Administration registration and modify the types of authorized pharmacological treatments.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. Section 11839.1 of the Health and Safety Code is amended to read:11839.1. The Legislature finds and declares that it is in the best interests of the health and welfare of the people of this state to coordinate narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatments for substance abuse disorders in the treatment of addicted persons whose addiction was acquired or supported by the use of a narcotic drug or drugs, not in compliance with a physician and surgeons legal prescription, and to establish and enforce minimum requirements for the operation of all narcotic these treatment programs in this state.SEC. 2. Section 11839.2 of the Health and Safety Code is amended to read:11839.2. The following controlled substances medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levoalphacetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other federally approved, controlled substances approved medications used for the purpose of narcotic replacement treatment. treatment and medication-assisted treatment.SEC. 3. Section 11839.6 of the Health and Safety Code is amended to read:11839.6. (a) The department shall establish a program for the operation and regulation of office-based narcotic treatment programs. An office-based narcotic treatment program established pursuant to this section shall meet either of the following conditions:(1) Hold a primary narcotic treatment program license.(2) Be affiliated and associated with a primary licensed narcotic treatment program. An office-based narcotic treatment program meeting the requirement of this paragraph shall not be required to have a license separate from the primary licensed narcotic treatment program with which it is affiliated and associated.(b) For purposes of this section, office-based narcotic treatment program means a program in which interested and knowledgeable physicians and surgeons provide addiction treatment services, and in which community pharmacies or medication units supply necessary medication both to these physicians and surgeons for distribution to patients and through direct administration and specified dispensing services.(c) Notwithstanding any other provision of law or regulation, including Section 10020 of Title 9 of the California Code of Regulations, an office-based narcotic treatment program in a remote site that is affiliated and associated with a licensed narcotic treatment program may be approved by the department, if all of the following conditions are met:(1) A physician may provide office-based addiction services only if each office-based patient is registered as a patient in the licensed narcotic treatment program and both the licensed narcotic treatment program and the office-based narcotic treatment program ensure that all services required under Chapter 4 (commencing with Section 10000) of Division 4 of Title 9 of the California Code of Regulations for the management of narcotic addiction are provided to all patients treated in the remote site.(2) A physician in an office-based narcotic treatment program may provide treatment for a maximum of 20 an appropriate number of patients under the appropriate United States Drug Enforcement Administration registration. The primary licensed narcotic treatment program shall be limited to its total licensed capacity as established by the department, including the patients of physicians in the office-based narcotic treatment program.(3) The physicians in the office-based narcotic treatment program shall dispense or administer pharmacologic treatment for narcotic addiction or a substance use disorder that has been approved by the federal Food and Drug Administration such as buprenorphine, levoalphacetylmethadol (LAAM) or methadone. (LAAM), methadone, naltrexone, or any other medication approved by the federal Food and Drug Administration.(4) Office-based narcotic treatment programs, in conjunction with primary licensed narcotic treatment programs, shall develop protocols to prevent the diversion of methadone. medication. The department may develop regulations to prevent the diversion of methadone. medication.(d) For purposes of this section, remote site means a site that is geographically or physically isolated from any licensed narcotic treatment program. Therefore, the requirements in this subdivision regarding a remote site do not apply to an office-based narcotic treatment program that holds a primary narcotic treatment program license.(e) In considering an office-based narcotic treatment program application, the department shall independently weigh the treatment needs and concerns of the county, city, or areas to be served by the program.(f) Nothing in this section is intended to expand the scope of the practice of pharmacy.
CALIFORNIA LEGISLATURE 20172018 REGULAR SESSION Assembly Bill No. 395Introduced by Assembly Member BocanegraFebruary 09, 2017 An act to amend Sections 11839.1, 11839.2, and 11839.6 of the Health and Safety Code, relating to public health. LEGISLATIVE COUNSEL'S DIGESTAB 395, as introduced, Bocanegra. Alcohol and drug treatment programs.Existing law generally requires the State Department of Health Care Services to be responsible for licensing narcotic treatment programs to use narcotic replacement therapy in the treatment of addicted persons and makes legislative findings in support of coordinated narcotic treatment programs in this regard. Existing law specifies the controlled substances a licensed narcotic treatment program may use for narcotic replacement therapy. Existing law authorizes the department to approve an office-based narcotic treatment program in a remote site, if certain conditions are met, that include among others, a physician at a remote site may treat up to a maximum number of 20 patients, who are provided with a specific pharmacological treatment.This bill would make legislative findings and declarations that it is in the best interest of the health and welfare of the people of this state to also coordinate medication-assisted treatments for substance abuse disorders. The bill would modify the specific controlled substances authorized for use in narcotic replacement therapy to include medication-assisted treatment and refer to medications, rather than controlled substances. The bill would modify the conditions for the department to authorize an office-based narcotic treatment program in a remote site to authorize a physician to treat a number of patients specified under the United States Drug Enforcement Administration registration and modify the types of authorized pharmacological treatments.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
CALIFORNIA LEGISLATURE 20172018 REGULAR SESSION
Assembly Bill No. 395
Introduced by Assembly Member BocanegraFebruary 09, 2017
Introduced by Assembly Member Bocanegra
February 09, 2017
An act to amend Sections 11839.1, 11839.2, and 11839.6 of the Health and Safety Code, relating to public health.
LEGISLATIVE COUNSEL'S DIGEST
## LEGISLATIVE COUNSEL'S DIGEST
AB 395, as introduced, Bocanegra. Alcohol and drug treatment programs.
Existing law generally requires the State Department of Health Care Services to be responsible for licensing narcotic treatment programs to use narcotic replacement therapy in the treatment of addicted persons and makes legislative findings in support of coordinated narcotic treatment programs in this regard. Existing law specifies the controlled substances a licensed narcotic treatment program may use for narcotic replacement therapy. Existing law authorizes the department to approve an office-based narcotic treatment program in a remote site, if certain conditions are met, that include among others, a physician at a remote site may treat up to a maximum number of 20 patients, who are provided with a specific pharmacological treatment.This bill would make legislative findings and declarations that it is in the best interest of the health and welfare of the people of this state to also coordinate medication-assisted treatments for substance abuse disorders. The bill would modify the specific controlled substances authorized for use in narcotic replacement therapy to include medication-assisted treatment and refer to medications, rather than controlled substances. The bill would modify the conditions for the department to authorize an office-based narcotic treatment program in a remote site to authorize a physician to treat a number of patients specified under the United States Drug Enforcement Administration registration and modify the types of authorized pharmacological treatments.
Existing law generally requires the State Department of Health Care Services to be responsible for licensing narcotic treatment programs to use narcotic replacement therapy in the treatment of addicted persons and makes legislative findings in support of coordinated narcotic treatment programs in this regard. Existing law specifies the controlled substances a licensed narcotic treatment program may use for narcotic replacement therapy. Existing law authorizes the department to approve an office-based narcotic treatment program in a remote site, if certain conditions are met, that include among others, a physician at a remote site may treat up to a maximum number of 20 patients, who are provided with a specific pharmacological treatment.
This bill would make legislative findings and declarations that it is in the best interest of the health and welfare of the people of this state to also coordinate medication-assisted treatments for substance abuse disorders. The bill would modify the specific controlled substances authorized for use in narcotic replacement therapy to include medication-assisted treatment and refer to medications, rather than controlled substances. The bill would modify the conditions for the department to authorize an office-based narcotic treatment program in a remote site to authorize a physician to treat a number of patients specified under the United States Drug Enforcement Administration registration and modify the types of authorized pharmacological treatments.
## Digest Key
## Bill Text
The people of the State of California do enact as follows:SECTION 1. Section 11839.1 of the Health and Safety Code is amended to read:11839.1. The Legislature finds and declares that it is in the best interests of the health and welfare of the people of this state to coordinate narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatments for substance abuse disorders in the treatment of addicted persons whose addiction was acquired or supported by the use of a narcotic drug or drugs, not in compliance with a physician and surgeons legal prescription, and to establish and enforce minimum requirements for the operation of all narcotic these treatment programs in this state.SEC. 2. Section 11839.2 of the Health and Safety Code is amended to read:11839.2. The following controlled substances medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levoalphacetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other federally approved, controlled substances approved medications used for the purpose of narcotic replacement treatment. treatment and medication-assisted treatment.SEC. 3. Section 11839.6 of the Health and Safety Code is amended to read:11839.6. (a) The department shall establish a program for the operation and regulation of office-based narcotic treatment programs. An office-based narcotic treatment program established pursuant to this section shall meet either of the following conditions:(1) Hold a primary narcotic treatment program license.(2) Be affiliated and associated with a primary licensed narcotic treatment program. An office-based narcotic treatment program meeting the requirement of this paragraph shall not be required to have a license separate from the primary licensed narcotic treatment program with which it is affiliated and associated.(b) For purposes of this section, office-based narcotic treatment program means a program in which interested and knowledgeable physicians and surgeons provide addiction treatment services, and in which community pharmacies or medication units supply necessary medication both to these physicians and surgeons for distribution to patients and through direct administration and specified dispensing services.(c) Notwithstanding any other provision of law or regulation, including Section 10020 of Title 9 of the California Code of Regulations, an office-based narcotic treatment program in a remote site that is affiliated and associated with a licensed narcotic treatment program may be approved by the department, if all of the following conditions are met:(1) A physician may provide office-based addiction services only if each office-based patient is registered as a patient in the licensed narcotic treatment program and both the licensed narcotic treatment program and the office-based narcotic treatment program ensure that all services required under Chapter 4 (commencing with Section 10000) of Division 4 of Title 9 of the California Code of Regulations for the management of narcotic addiction are provided to all patients treated in the remote site.(2) A physician in an office-based narcotic treatment program may provide treatment for a maximum of 20 an appropriate number of patients under the appropriate United States Drug Enforcement Administration registration. The primary licensed narcotic treatment program shall be limited to its total licensed capacity as established by the department, including the patients of physicians in the office-based narcotic treatment program.(3) The physicians in the office-based narcotic treatment program shall dispense or administer pharmacologic treatment for narcotic addiction or a substance use disorder that has been approved by the federal Food and Drug Administration such as buprenorphine, levoalphacetylmethadol (LAAM) or methadone. (LAAM), methadone, naltrexone, or any other medication approved by the federal Food and Drug Administration.(4) Office-based narcotic treatment programs, in conjunction with primary licensed narcotic treatment programs, shall develop protocols to prevent the diversion of methadone. medication. The department may develop regulations to prevent the diversion of methadone. medication.(d) For purposes of this section, remote site means a site that is geographically or physically isolated from any licensed narcotic treatment program. Therefore, the requirements in this subdivision regarding a remote site do not apply to an office-based narcotic treatment program that holds a primary narcotic treatment program license.(e) In considering an office-based narcotic treatment program application, the department shall independently weigh the treatment needs and concerns of the county, city, or areas to be served by the program.(f) Nothing in this section is intended to expand the scope of the practice of pharmacy.
The people of the State of California do enact as follows:
## The people of the State of California do enact as follows:
SECTION 1. Section 11839.1 of the Health and Safety Code is amended to read:11839.1. The Legislature finds and declares that it is in the best interests of the health and welfare of the people of this state to coordinate narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatments for substance abuse disorders in the treatment of addicted persons whose addiction was acquired or supported by the use of a narcotic drug or drugs, not in compliance with a physician and surgeons legal prescription, and to establish and enforce minimum requirements for the operation of all narcotic these treatment programs in this state.
SECTION 1. Section 11839.1 of the Health and Safety Code is amended to read:
### SECTION 1.
11839.1. The Legislature finds and declares that it is in the best interests of the health and welfare of the people of this state to coordinate narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatments for substance abuse disorders in the treatment of addicted persons whose addiction was acquired or supported by the use of a narcotic drug or drugs, not in compliance with a physician and surgeons legal prescription, and to establish and enforce minimum requirements for the operation of all narcotic these treatment programs in this state.
11839.1. The Legislature finds and declares that it is in the best interests of the health and welfare of the people of this state to coordinate narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatments for substance abuse disorders in the treatment of addicted persons whose addiction was acquired or supported by the use of a narcotic drug or drugs, not in compliance with a physician and surgeons legal prescription, and to establish and enforce minimum requirements for the operation of all narcotic these treatment programs in this state.
11839.1. The Legislature finds and declares that it is in the best interests of the health and welfare of the people of this state to coordinate narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatments for substance abuse disorders in the treatment of addicted persons whose addiction was acquired or supported by the use of a narcotic drug or drugs, not in compliance with a physician and surgeons legal prescription, and to establish and enforce minimum requirements for the operation of all narcotic these treatment programs in this state.
11839.1. The Legislature finds and declares that it is in the best interests of the health and welfare of the people of this state to coordinate narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatments for substance abuse disorders in the treatment of addicted persons whose addiction was acquired or supported by the use of a narcotic drug or drugs, not in compliance with a physician and surgeons legal prescription, and to establish and enforce minimum requirements for the operation of all narcotic these treatment programs in this state.
SEC. 2. Section 11839.2 of the Health and Safety Code is amended to read:11839.2. The following controlled substances medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levoalphacetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other federally approved, controlled substances approved medications used for the purpose of narcotic replacement treatment. treatment and medication-assisted treatment.
SEC. 2. Section 11839.2 of the Health and Safety Code is amended to read:
### SEC. 2.
11839.2. The following controlled substances medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levoalphacetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other federally approved, controlled substances approved medications used for the purpose of narcotic replacement treatment. treatment and medication-assisted treatment.
11839.2. The following controlled substances medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levoalphacetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other federally approved, controlled substances approved medications used for the purpose of narcotic replacement treatment. treatment and medication-assisted treatment.
11839.2. The following controlled substances medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levoalphacetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other federally approved, controlled substances approved medications used for the purpose of narcotic replacement treatment. treatment and medication-assisted treatment.
11839.2. The following controlled substances medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:
(a) Methadone.
(b) Levoalphacetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.
(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.
(d) Any other federally approved, controlled substances approved medications used for the purpose of narcotic replacement treatment. treatment and medication-assisted treatment.
SEC. 3. Section 11839.6 of the Health and Safety Code is amended to read:11839.6. (a) The department shall establish a program for the operation and regulation of office-based narcotic treatment programs. An office-based narcotic treatment program established pursuant to this section shall meet either of the following conditions:(1) Hold a primary narcotic treatment program license.(2) Be affiliated and associated with a primary licensed narcotic treatment program. An office-based narcotic treatment program meeting the requirement of this paragraph shall not be required to have a license separate from the primary licensed narcotic treatment program with which it is affiliated and associated.(b) For purposes of this section, office-based narcotic treatment program means a program in which interested and knowledgeable physicians and surgeons provide addiction treatment services, and in which community pharmacies or medication units supply necessary medication both to these physicians and surgeons for distribution to patients and through direct administration and specified dispensing services.(c) Notwithstanding any other provision of law or regulation, including Section 10020 of Title 9 of the California Code of Regulations, an office-based narcotic treatment program in a remote site that is affiliated and associated with a licensed narcotic treatment program may be approved by the department, if all of the following conditions are met:(1) A physician may provide office-based addiction services only if each office-based patient is registered as a patient in the licensed narcotic treatment program and both the licensed narcotic treatment program and the office-based narcotic treatment program ensure that all services required under Chapter 4 (commencing with Section 10000) of Division 4 of Title 9 of the California Code of Regulations for the management of narcotic addiction are provided to all patients treated in the remote site.(2) A physician in an office-based narcotic treatment program may provide treatment for a maximum of 20 an appropriate number of patients under the appropriate United States Drug Enforcement Administration registration. The primary licensed narcotic treatment program shall be limited to its total licensed capacity as established by the department, including the patients of physicians in the office-based narcotic treatment program.(3) The physicians in the office-based narcotic treatment program shall dispense or administer pharmacologic treatment for narcotic addiction or a substance use disorder that has been approved by the federal Food and Drug Administration such as buprenorphine, levoalphacetylmethadol (LAAM) or methadone. (LAAM), methadone, naltrexone, or any other medication approved by the federal Food and Drug Administration.(4) Office-based narcotic treatment programs, in conjunction with primary licensed narcotic treatment programs, shall develop protocols to prevent the diversion of methadone. medication. The department may develop regulations to prevent the diversion of methadone. medication.(d) For purposes of this section, remote site means a site that is geographically or physically isolated from any licensed narcotic treatment program. Therefore, the requirements in this subdivision regarding a remote site do not apply to an office-based narcotic treatment program that holds a primary narcotic treatment program license.(e) In considering an office-based narcotic treatment program application, the department shall independently weigh the treatment needs and concerns of the county, city, or areas to be served by the program.(f) Nothing in this section is intended to expand the scope of the practice of pharmacy.
SEC. 3. Section 11839.6 of the Health and Safety Code is amended to read:
### SEC. 3.
11839.6. (a) The department shall establish a program for the operation and regulation of office-based narcotic treatment programs. An office-based narcotic treatment program established pursuant to this section shall meet either of the following conditions:(1) Hold a primary narcotic treatment program license.(2) Be affiliated and associated with a primary licensed narcotic treatment program. An office-based narcotic treatment program meeting the requirement of this paragraph shall not be required to have a license separate from the primary licensed narcotic treatment program with which it is affiliated and associated.(b) For purposes of this section, office-based narcotic treatment program means a program in which interested and knowledgeable physicians and surgeons provide addiction treatment services, and in which community pharmacies or medication units supply necessary medication both to these physicians and surgeons for distribution to patients and through direct administration and specified dispensing services.(c) Notwithstanding any other provision of law or regulation, including Section 10020 of Title 9 of the California Code of Regulations, an office-based narcotic treatment program in a remote site that is affiliated and associated with a licensed narcotic treatment program may be approved by the department, if all of the following conditions are met:(1) A physician may provide office-based addiction services only if each office-based patient is registered as a patient in the licensed narcotic treatment program and both the licensed narcotic treatment program and the office-based narcotic treatment program ensure that all services required under Chapter 4 (commencing with Section 10000) of Division 4 of Title 9 of the California Code of Regulations for the management of narcotic addiction are provided to all patients treated in the remote site.(2) A physician in an office-based narcotic treatment program may provide treatment for a maximum of 20 an appropriate number of patients under the appropriate United States Drug Enforcement Administration registration. The primary licensed narcotic treatment program shall be limited to its total licensed capacity as established by the department, including the patients of physicians in the office-based narcotic treatment program.(3) The physicians in the office-based narcotic treatment program shall dispense or administer pharmacologic treatment for narcotic addiction or a substance use disorder that has been approved by the federal Food and Drug Administration such as buprenorphine, levoalphacetylmethadol (LAAM) or methadone. (LAAM), methadone, naltrexone, or any other medication approved by the federal Food and Drug Administration.(4) Office-based narcotic treatment programs, in conjunction with primary licensed narcotic treatment programs, shall develop protocols to prevent the diversion of methadone. medication. The department may develop regulations to prevent the diversion of methadone. medication.(d) For purposes of this section, remote site means a site that is geographically or physically isolated from any licensed narcotic treatment program. Therefore, the requirements in this subdivision regarding a remote site do not apply to an office-based narcotic treatment program that holds a primary narcotic treatment program license.(e) In considering an office-based narcotic treatment program application, the department shall independently weigh the treatment needs and concerns of the county, city, or areas to be served by the program.(f) Nothing in this section is intended to expand the scope of the practice of pharmacy.
11839.6. (a) The department shall establish a program for the operation and regulation of office-based narcotic treatment programs. An office-based narcotic treatment program established pursuant to this section shall meet either of the following conditions:(1) Hold a primary narcotic treatment program license.(2) Be affiliated and associated with a primary licensed narcotic treatment program. An office-based narcotic treatment program meeting the requirement of this paragraph shall not be required to have a license separate from the primary licensed narcotic treatment program with which it is affiliated and associated.(b) For purposes of this section, office-based narcotic treatment program means a program in which interested and knowledgeable physicians and surgeons provide addiction treatment services, and in which community pharmacies or medication units supply necessary medication both to these physicians and surgeons for distribution to patients and through direct administration and specified dispensing services.(c) Notwithstanding any other provision of law or regulation, including Section 10020 of Title 9 of the California Code of Regulations, an office-based narcotic treatment program in a remote site that is affiliated and associated with a licensed narcotic treatment program may be approved by the department, if all of the following conditions are met:(1) A physician may provide office-based addiction services only if each office-based patient is registered as a patient in the licensed narcotic treatment program and both the licensed narcotic treatment program and the office-based narcotic treatment program ensure that all services required under Chapter 4 (commencing with Section 10000) of Division 4 of Title 9 of the California Code of Regulations for the management of narcotic addiction are provided to all patients treated in the remote site.(2) A physician in an office-based narcotic treatment program may provide treatment for a maximum of 20 an appropriate number of patients under the appropriate United States Drug Enforcement Administration registration. The primary licensed narcotic treatment program shall be limited to its total licensed capacity as established by the department, including the patients of physicians in the office-based narcotic treatment program.(3) The physicians in the office-based narcotic treatment program shall dispense or administer pharmacologic treatment for narcotic addiction or a substance use disorder that has been approved by the federal Food and Drug Administration such as buprenorphine, levoalphacetylmethadol (LAAM) or methadone. (LAAM), methadone, naltrexone, or any other medication approved by the federal Food and Drug Administration.(4) Office-based narcotic treatment programs, in conjunction with primary licensed narcotic treatment programs, shall develop protocols to prevent the diversion of methadone. medication. The department may develop regulations to prevent the diversion of methadone. medication.(d) For purposes of this section, remote site means a site that is geographically or physically isolated from any licensed narcotic treatment program. Therefore, the requirements in this subdivision regarding a remote site do not apply to an office-based narcotic treatment program that holds a primary narcotic treatment program license.(e) In considering an office-based narcotic treatment program application, the department shall independently weigh the treatment needs and concerns of the county, city, or areas to be served by the program.(f) Nothing in this section is intended to expand the scope of the practice of pharmacy.
11839.6. (a) The department shall establish a program for the operation and regulation of office-based narcotic treatment programs. An office-based narcotic treatment program established pursuant to this section shall meet either of the following conditions:(1) Hold a primary narcotic treatment program license.(2) Be affiliated and associated with a primary licensed narcotic treatment program. An office-based narcotic treatment program meeting the requirement of this paragraph shall not be required to have a license separate from the primary licensed narcotic treatment program with which it is affiliated and associated.(b) For purposes of this section, office-based narcotic treatment program means a program in which interested and knowledgeable physicians and surgeons provide addiction treatment services, and in which community pharmacies or medication units supply necessary medication both to these physicians and surgeons for distribution to patients and through direct administration and specified dispensing services.(c) Notwithstanding any other provision of law or regulation, including Section 10020 of Title 9 of the California Code of Regulations, an office-based narcotic treatment program in a remote site that is affiliated and associated with a licensed narcotic treatment program may be approved by the department, if all of the following conditions are met:(1) A physician may provide office-based addiction services only if each office-based patient is registered as a patient in the licensed narcotic treatment program and both the licensed narcotic treatment program and the office-based narcotic treatment program ensure that all services required under Chapter 4 (commencing with Section 10000) of Division 4 of Title 9 of the California Code of Regulations for the management of narcotic addiction are provided to all patients treated in the remote site.(2) A physician in an office-based narcotic treatment program may provide treatment for a maximum of 20 an appropriate number of patients under the appropriate United States Drug Enforcement Administration registration. The primary licensed narcotic treatment program shall be limited to its total licensed capacity as established by the department, including the patients of physicians in the office-based narcotic treatment program.(3) The physicians in the office-based narcotic treatment program shall dispense or administer pharmacologic treatment for narcotic addiction or a substance use disorder that has been approved by the federal Food and Drug Administration such as buprenorphine, levoalphacetylmethadol (LAAM) or methadone. (LAAM), methadone, naltrexone, or any other medication approved by the federal Food and Drug Administration.(4) Office-based narcotic treatment programs, in conjunction with primary licensed narcotic treatment programs, shall develop protocols to prevent the diversion of methadone. medication. The department may develop regulations to prevent the diversion of methadone. medication.(d) For purposes of this section, remote site means a site that is geographically or physically isolated from any licensed narcotic treatment program. Therefore, the requirements in this subdivision regarding a remote site do not apply to an office-based narcotic treatment program that holds a primary narcotic treatment program license.(e) In considering an office-based narcotic treatment program application, the department shall independently weigh the treatment needs and concerns of the county, city, or areas to be served by the program.(f) Nothing in this section is intended to expand the scope of the practice of pharmacy.
11839.6. (a) The department shall establish a program for the operation and regulation of office-based narcotic treatment programs. An office-based narcotic treatment program established pursuant to this section shall meet either of the following conditions:
(1) Hold a primary narcotic treatment program license.
(2) Be affiliated and associated with a primary licensed narcotic treatment program. An office-based narcotic treatment program meeting the requirement of this paragraph shall not be required to have a license separate from the primary licensed narcotic treatment program with which it is affiliated and associated.
(b) For purposes of this section, office-based narcotic treatment program means a program in which interested and knowledgeable physicians and surgeons provide addiction treatment services, and in which community pharmacies or medication units supply necessary medication both to these physicians and surgeons for distribution to patients and through direct administration and specified dispensing services.
(c) Notwithstanding any other provision of law or regulation, including Section 10020 of Title 9 of the California Code of Regulations, an office-based narcotic treatment program in a remote site that is affiliated and associated with a licensed narcotic treatment program may be approved by the department, if all of the following conditions are met:
(1) A physician may provide office-based addiction services only if each office-based patient is registered as a patient in the licensed narcotic treatment program and both the licensed narcotic treatment program and the office-based narcotic treatment program ensure that all services required under Chapter 4 (commencing with Section 10000) of Division 4 of Title 9 of the California Code of Regulations for the management of narcotic addiction are provided to all patients treated in the remote site.
(2) A physician in an office-based narcotic treatment program may provide treatment for a maximum of 20 an appropriate number of patients under the appropriate United States Drug Enforcement Administration registration. The primary licensed narcotic treatment program shall be limited to its total licensed capacity as established by the department, including the patients of physicians in the office-based narcotic treatment program.
(3) The physicians in the office-based narcotic treatment program shall dispense or administer pharmacologic treatment for narcotic addiction or a substance use disorder that has been approved by the federal Food and Drug Administration such as buprenorphine, levoalphacetylmethadol (LAAM) or methadone. (LAAM), methadone, naltrexone, or any other medication approved by the federal Food and Drug Administration.
(4) Office-based narcotic treatment programs, in conjunction with primary licensed narcotic treatment programs, shall develop protocols to prevent the diversion of methadone. medication. The department may develop regulations to prevent the diversion of methadone. medication.
(d) For purposes of this section, remote site means a site that is geographically or physically isolated from any licensed narcotic treatment program. Therefore, the requirements in this subdivision regarding a remote site do not apply to an office-based narcotic treatment program that holds a primary narcotic treatment program license.
(e) In considering an office-based narcotic treatment program application, the department shall independently weigh the treatment needs and concerns of the county, city, or areas to be served by the program.
(f) Nothing in this section is intended to expand the scope of the practice of pharmacy.